OS Therapies Inc

Clinical-stage osteosarcoma immunotherapy developer with a positive pivotal readout but an acute going-concern funding cliff.

Strengths

• Phase IIb OST-HER2 met its primary endpoint with statistical significance; 2-yr OS 75% vs 40% control (p<0.0001) — materially de-risking
• Advancing toward BLA/accelerated approval with orphan and rare-pediatric designations (potential priority review voucher)

Risks

• Going-concern doubt and near-zero liquidity (current ratio 0.028, 2.2th pct); no product revenue
• Positive data is Phase IIb (not confirmatory Phase 3) and approval/financing remain binary

Notable findings

• Going concern● Our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern
• Weak liquidityCurrent ratio 0.03 (<1)
• Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
• Notable holderHeld by 2 notable fund(s): STATE STREET CORP, FMR LLC (as of 2026-03-31)
• New fund positionNotable fund(s) opened this quarter: FMR LLC